Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99

FDA recall notice · announced November 14, 2018 · Orexigen Therapeutics

Class III FDA/FSIS Class III: use is not likely to cause adverse health consequences.

The product

Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99

Reason for recall

Container packaging defect.

Notes

Distribution: Within the United States
Lot/code information: Lot #: ZYCY, Exp. 04/11/2021
Quantity: 18,895 bottles
Status: Terminated
Products in this recall event:
- Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99 (D-0219-2019)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.